“I’m asking for help to pursue treatment at the Immunocine Cancer Center in Mexico.” That is how Dennis Pepa, a founding member of the thrash band Death Angel, framed his fundraiser. Pepa was diagnosed with Stage 4 duodenal cancer in February 2026, and he had already lost a job he held for almost 20 years. His goal is $150,000, to cover treatment, travel, lodging and support for his family.
The clinic reached a wider audience in October 2026 through a paid-partnership Instagram reel. So the question is a plain one: what does a dendritic cell vaccine do, and what has actually been shown?
One approved product
Sipuleucel-T is the only FDA-approved dendritic cell vaccine. It is used for some men with advanced prostate cancer, specifically cancer that has spread to other parts of the body and no longer responds to hormone treatment. Most other dendritic cell vaccines are still being tested in clinical trials.
A 2015 evidence review in Core Evidence looked at the four placebo-controlled, randomized trials behind sipuleucel-T. Three were in metastatic castration-resistant prostate cancer, and all three showed improved overall survival. None showed meaningful drops in symptoms, tumor volumes or prostate-specific antigen levels. The reviewers noted it is indicated for patients with no or mild symptoms because it has never shown a direct effect on the cancer. Side effects in all four studies centered on cytokine release, and cancer vaccines in general can cause flu-like symptoms. How bad they get depends on the patient’s health, the cancer type and stage, and the dose.
How the vaccines are meant to work
Treatment vaccines differ from preventive ones. They are given to people who already have cancer, and they target the tumor itself. The logic rests on tumor-associated antigens, substances that are absent from normal cells or present at lower levels. A vaccine tries to teach the immune system to spot those antigens and destroy the cells carrying them.
One of the three main ways to make such a vaccine uses the patient’s own dendritic cells, a type of immune cell.
What Immunocine says it offers
Everything in this section comes from Immunocine’s own description of its treatment. It has not been independently verified here.
The clinic says it was founded for patients who cannot join clinical trials. Its protocol, called IDCT, starts in the lab with a sample of the tumor and the patient’s white blood cells. The tumor is broken down into mRNA and antigens specific to that cancer. Immunocine says the mRNA goes inside the dendritic cells, giving them what it calls “blueprint” information, while the antigens sit on the outside. The clinic calls this “Double Loading” and says it mimics a viral-like infection, prompting the dendritic cells to alert Natural Killer cells and Killer T cells.
The clinic also states that the treatment adds no foreign compounds or genetically modified cells, that using the patient’s own cells significantly lowers the risk of side effects, and that the immune response continues after the last treatment. It describes the course as lasting six weeks. Patients can stay in Mexico throughout or go home between appointments and come back.
Pepa describes the clinic in similar terms, saying it uses a patient’s own immune cells and tumor material to prepare a personalized treatment. On cost, he cites a public listing from Heal Navigator that puts Immunocine’s treatment at $120,000. He says he still has to confirm his own price, and that the clinic’s team must first agree he can go ahead.
A benefit concert, “Heal As One: A Benefit For Dennis Pepa,” is set for Sunday, January 24, 2027, at DNA Lounge in San Francisco.
Anyone weighing a treatment outside a clinical trial should talk to their oncologist before considering it.
Sources
- Welcome to the Future of Cancer Treatment
- Cancer Treatment Vaccines – Immunotherapy
- Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
- Thrash Metal Veterans Join Forces For 'Heal As One' Benefit Concert Supporting DEATH ANGEL's DENNIS PEPA
Photo: Rhoda Baer (Photographer) (Public domain)
